Immunotherapy, as exemplified by immune checkpoint inhibitors (ICIs) such as PD-1–blocking antibodies, has become the standard of care for a wide variety of cancer types, and the immunological profile of the tumor microenvironment (TME) is becoming increasingly important to optimize combination treatment with ICIs (1, 2). This evidence concerns the gene PDCD1 and cancer.